Previous 10 | Next 10 |
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant...
Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference Canada NewsWire HAMILTON, ON and BOSTON , Feb. 13, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-gener...
The following slide deck was published by Fusion Pharmaceuticals Inc. in conjunction with this event. For further details see: Fusion Pharmaceuticals (FUSN) Investor Presentation - Slideshow
Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights Canada NewsWire FPI-2068 IND expected to be submitted in the first quarter of 2023 FPI-1434 Phase 1 data expected in the second quarter of 2023 FPI-1966 Phase 1 study open and enro...
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies Canada NewsWire - Agreement augments Fusion's existing isotope supply as pipeline of clinical stage actinium-based radiopharmaceuticals grows ...
Fusion Pharmaceuticals press release ( NASDAQ: FUSN ): Q3 GAAP EPS of -$0.55 misses by $0.04 . Revenue of $0.17M (-46.9% Y/Y) beats by $0.07M . As of September 30, 2022, Fusion held cash, cash equivalents and investments of $205.5 million, compared to cash, cas...
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates Canada NewsWire FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expr...
Fusion Pharmaceuticals ( NASDAQ: FUSN ) on Monday said it had appointed Dmitri Bobilev as its chief medical officer. According to FUSN, Bobilev has more than a decade of experience as a practicing medical and radiation oncologist. Bobilev joins FUSN from Checkmate Phar...
Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer Canada NewsWire HAMILTON , ON and BOSTON , Nov. 7, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing ne...
Summary Two new Breakout Stocks for Week 39 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now down to +108.7% YTD. This week no picks beat 10% gains in less than a week with SLCR peak at +7.1% and continuing the highest negative Mom...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...